Premium
Anti‐centromere antibody‐positive Sjögren's syndrome: A distinct clinical subgroup?
Author(s) -
Lee KyungEun,
Kang JiHyoun,
Lee JeongWon,
Wen Lihui,
Park DongJin,
Kim TaeJong,
Park YongWook,
Lee ShinSeok
Publication year - 2015
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.12684
Subject(s) - medicine , sclerodactyly , autoantibody , antibody , rheumatism , rheumatology , gastroenterology , systemic disease , disease , dermatology , immunology , calcinosis , calcification
Aim To investigate whether patients with Sjögren's syndrome ( SS ) can be distinguished based on the positivity of anti‐centromere antibody ( ACA ), and if so, whether the subgroups differ in their clinical and laboratory features. Methods Eleven patients with ACA ‐positive and 71 patients ACA ‐negative SS were examined. All patients had minor salivary gland biopsy; sociodemographic data, glandular and extraglandular manifestations, and laboratory findings, including autoantibodies, complement and immunoglobulin levels, were analyzed. European League Against Rheumatism SS disease activity index ( ESSDAI ) and SS disease damage index ( SSDDI ) were also measured. Results The prevalence of ACA among SS patients was 13.4%. ACA ‐positive SS patients had a higher prevalence of Raynaud's phenomenon, sclerodactyly and autoimmune thyroiditis and a lower prevalence of anti‐ SSA /Ro and anti‐ SSB /La antibodies compared to ACA ‐negative patients. Disease activity was higher in ACA ‐positive patients than in ACA ‐negative patients, but the damage index did not differ between the two groups. None of the patients who originally had ACA evolved to having full‐blown systemic sclerosis. Conclusion Patients with SS who have ACA differ from classic SS patients in several clinical and laboratory parameters. ACA should be considered one of the pathogenically relevant autoantibodies for SS .